Browsing Tag
Elecsys pTau217
2 posts
Roche (SIX: ROP) sales rise 7% as pipeline hopes meet a near-record valuation
Roche delivered 7% constant-currency Q3 sales growth and maintained 2026 guidance as newer medicines offset patent erosion. With ROP touching a 52-week high and key medicines still awaiting regulatory decisions, pipeline conversion is becoming the next valuation test.
Elecsys pTau217 wins FDA clearance as Roche pushes Alzheimer’s testing into primary care
Roche has secured FDA clearance for Elecsys pTau217, giving more than 4,500 existing U.S. cobas analyzers a potential role in assessing Alzheimer’s amyloid pathology through a routine blood draw.